REFERENCES
1. Tanos V., Berry K.E., Seikkula J., Abi Raad E., Stavroulis A., Sleiman Z. The management of polyps in female reproductive organs. Int J Surg. 2017; 43: 7–16. DOI: https://doi.org/10.1016/j.ijsu.2017.05.012
2. Yuksel S. Endometrial polyps: Is the prediction of spontaneous regression possible? Obstet Gynecol Sci. 2021; 64 (1): 114–21. DOI: https://doi.org/10.5468/ogs.20242
3. Chernukha G.E., Asaturova A.V., Ivanov I.A., Dumanovskaya M. R. The structure of endometrial pathology in various age periods. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2018; (8): 129–35. DOI: https://doi.org/10.18565/aig.2018.8.129-134 (in Russian)
4. Capmas P., Pourcelot A.G., Giral E., Fedida D., Fernandez H. Office hysteroscopy: a report of 2402 cases. J Gynecol Obstet Biol Reprod (Paris). 2016; 45: 445–50. DOI: https://doi.org/10.1016/j.jgyn.2016.02.007
5. Dreisler E., Stampe Sorensen S., Ibsen P.H., Lose G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Ultrasound Obstet Gynecol. 2009; 33: 102–8. DOI: https://doi.org/10.1002/uog.6259
6. Moon S.H., Lee S.E., Jung I.K. A giant endometrial polyp with tamoxifen therapy in postmenopausal woman. Korean J Obstet Gynecol. 2011; 54 (12): 836–40. DOI: https://doi.org/10.5468/KJOG.2011.54.12.836
7. Bakour S.H., Khan K.S., Gupta J.K. The risk of premalignant and malignant pathology in endometrial polyps. Acta Obstet Gynecol Scand. 2000; 79 (4): 317–20. PMID: 10746849.
8. Lopes R.G., Baracat E.C., de Albuquerque Neto L.C. Analysis of estrogen- and progesterone-receptor expression in endometrial polyps. J Minim Invasive Gynecol. 2007; 14 (3): 300–3. DOI: https://doi.org/10.1016/j.jmig.2006.10.022
9. Mittal K., Schwartz L., Goswami S. Estrogen and progesterone receptor expression in endometrial polyps. Int J Gynecol Pathol. 1996; 15 (4): 345–8. DOI: https://doi.org/10.1097/00004347-199610000-00007
10. Chan S.S., Tam W.H., Yeo W. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG. 2007; 114 (12): 1510–5. DOI: https://doi.org/10.1111/j.1471-0528.2007.01545.x
11. Nijkang N.P. Endometrial polyps: pathogenesis, sequelae and treatment. SAGE Open Med. 2019; 7: 1–12. DOI: https://doi.org/10.1177/2050312119848247
12. McGurgan P., Taylor L.J., Duffy S.R. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen. Maturitas. 2006; 54 (3): 252–9. DOI: https://doi.org/10.1016/j.maturitas.2005.11.007
13. Gokmen Karasu A.F., Sonmez F.C., Aydin S. Survivin expression in simple endometrial polyps and tamoxifen-associated endometrial polyps. Int J Gynecol Pathol. 2018; 37 (1): 27–31. DOI: https://doi.org/10.1097/PGP.0000000000000376
14. Goldstein S.R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1994; 170 (2): 447–51. DOI: https://doi.org/10.1016/s0002-9378(94)70209-8
15. Oguz S., Sargin A., Kelekci S., Aytan H., Tapisiz O.L., Mollamahmutoglu L. The role of hormone replacement therapy in endometrial polyp formation. Maturitas. 2005; 50: 231–6. DOI: https://doi.org/10.1016/j.maturitas.2004.06.002
16. Hassa H. Independent risk factors for endometrial polyps: diabetes, hypertension, and obesity. Asian Pac J Reprod. 2012; 1 (4): 312–4. DOI: https://doi.org/10.1016/S2305-0500(13)60099-8
17. Nappi L., Indraccolo I. Are diabetes, hypertension, and obesity independent risk factors for endometrial polyps? J Minim Invasive Gynecol. 2009; 16 (2): 157–62. DOI: https://doi.org/10.1016/j.jmig.2008.11.004
18. Gregoriou O., Konidaris S., Vrachnis N. Clinical parameters linked with malignancy in endometrial polyps. Climacteric. 2009; 12 (5): 454–8. DOI: https://doi.org/10.1080/13697130902912605
19. Bagdasaryan L.Yu., Ponomarev V.V., Karakhalis L.Yu., Steblo E.I., Pen- zhoyan G.A. Factors influencing the development of endometrial polyps. Kubanskiy nauchniy meditsinskiy vestnik [Kuban Scientific Medical Bulletin]. 2018; 25 (2): 25–8. DOI: https://doi.org/10.25207/1608-6228-2018-25-2-25-28 (in Russian)
20. Tabrizi A.D. Histologic features and differential diagnosis of endometrial polyps; an update and review. Int J Womens Health Reprod Sci. 2016; 4 (4): 152–6. DOI: https://doi.org/10.15296/ijwhr.2016.35
21. Annan J.J., Aquilina J., Ball E. The management of endometrial polyps in the 21st century. Obstet Gynaecol. 2012; 14 (1): 33–8. DOI: https://doi.org/10.1111/j.1744-4667.2011.00091.x
22. Taylor L.J., Jackson T.L., Reid J.G. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps. BJOG. 2003; 110 (9): 794–8. DOI: https://doi.org/10.1590/1516-3180.2018.0346.R4.19112019
23. Mourits M.J.E., Hollema H., De Vries E.G. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol. 2002; 33 (3): 341–6. DOI: https://doi.org/10.1053/hupa.2002.32226
24. Altaner S., Gucer F., Tokatli F. Expression of Bcl-2 and Ki-67 in tamoxifen-associated endometrial polyps: comparison with postmenopausal polyps. Onkologie. 2006; 29 (8–9): 376–80. DOI: https://doi.org/10.1159/000094443
25. Antunes A. Jr, Andrade L.A., Pinto G.A., et al. Is the immunohistochemical expression of proliferation (Ki-67) and apoptosis (Bcl-2) markers and cyclooxigenase-2 (COX-2) related to carcinogenesis in postmenopausal endometrial polyps? Anal Quant Cytopathol Histpathol. 2012; 34 (5): 264–72. PMID: 23301386.
26. Hu J., Yuan R. The expression levels of stem cell markers importin13, c-kit, CD146, and telomerase are decreased in endometrial polyps. Med Sci Monit. 2011; 17 (8): BR221–7. DOI: https://doi.org/10.12659/msm.881901
27. Banas T., Pitynski K., Mikos M. Endometrial polyps and benign endometrial hyperplasia have increased prevalence of DNA fragmentation factors 40 and 45 (DFF40 and DFF45). together with the antiapoptotic B-cell lymphoma (Bcl-2) protein compared with normal human endometria. Int J Gynecol Pathol. 2018; 37 (5): 431–40. DOI: https://doi.org/10.1097/PGP.0000000000000442
28. Miranda S.P., Traiman P., Candido E.B. Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen. Int J Gynecol Cancer. 2010; 20 (9): 1525–30. DOI: https://doi.org/10.1111/IGC.0b013e3181f7b33b
29. Al-Jefout M., Black K., Schulke L. Novel finding of high density of activated mast cells in endometrial polyps. Fertil Steril. 2009; 92 (3): 1104–6. DOI: https://doi.org/10.1016/j.fertnstert.2009.02.016
30. El-Hamarneh T., Hey-Cunningham A.J., Berbic M. Cellular immune environment in endometrial polyps. Fertil Steril. 2013; 100 (5): 1364–72. DOI: https://doi.org/10.1016/j.fertnstert.2013.06.050
31. Norrby K. Mast cells and angiogenesis. APMIS. 2002; 110 (5): 355–71. DOI: https://doi.org/10.1034/j.1600-0463.2002.100501.x
32. Belov A.I., Ponomareva N.A. Risk factors for the development of endometrial polyps in women of different age groups. Molodezh – prakticheskomu zdravookhraneniyu [Youth – Practical Health Care]. 2019: 23–8. eLIBRARY ID: 42461478. (in Russian)
33. Richlin S.S., Ramachandran S., Shanti A., Murphy A.A., Parthasarathy S. Glycodelin levels in uterine flushings and in plasma of patients with leiomyomas and polyps: implications for implantation. Hum Reprod. 2002; 17 (10): 2742–7. DOI: https://doi.org/10.1093/humrep/17.10.2742
34. Stenchever M.A., Droegemueller W., Herbst A.L., Mishell D.R. Benign gynecologic lesions. In: Comprehensive Gynecology. St Louicis: Mosby, 2001: 495–7. DOI: https://doi.org/10.1016/S0015-0282(01)02972-7
35. Dal Cin P., Vanni R., Marras S. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res. 1995; 55 (7): 1565–8. PMID: 7882366.
36. Xuebing P., TinChiu L., Enlan X., Jing L., Xiaowu H. Is endometrial polyp formation associated with increased expression of vascular endothelial growth factor and transforming growth factor-beta1? Eur J Obstet Gynecol Reprod Biol. 2011; 159 (1): 198–203. DOI: https://doi.org/10.1016/j.ejogrb.2011.06.036
37. Stewart C.J., Bharat C., Crook M. p16 immunoreactivity in endometrial stromal cells: stromal p16 expression characterises but is not specific for endometrial polyps. Pathology. 2015; 47 (2): 112–7. DOI: https://doi.org/10.1097/PAT.0000000000000211
38. Takeda T. Mutations of RAS genes in endometrial polyps. Oncol Rep. 2019; 42 (6): 2303–8. DOI: https://doi.org/10.3892/or.2019.7353
39. Wang J., Zhao J., Lin J. Opportunities and risk factors for premalignant and malignant transformation of endometrial polyps: management strategies. J Minim Invasive Gynecol. 2010; 17: 53–8. DOI: https://doi.org/10.1016/j.jmig.2009.10.
40. Ferrazzi E., Zupi E., Leone F.P., Savelli L., Omodei U., Moscarini M., et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol. 2009; 200: 235.e1–6. DOI: https://doi.org/10.1016/j.ajog.2008.09.876